Therefore, further studies are warranted to assess the applicability of using the expression of αT-catenin and plakophilin-2 to differentiate patients with non-ischemic cardiomyopathy rather than ARVC. This evidence concerns the gene PKP2 and ischemic cardiomyopathy.